FDA.reportPublic FDA data

INSULIN ASPART

Substance profile for UNII D933668QVX, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for INSULIN ASPART
Structure render from PubChem CID 118984445

Substance Identity#

UNII
D933668QVX
Preferred term
INSULIN ASPART
Registry number
116094-23-6
Ingredient type
INGREDIENT SUBSTANCE
Chemical structure for INSULIN ASPART
Structure render from PubChem CID 118984445

Chemical And Database Identifiers#

RxCUI
51428
PubChem
118984445
NCIt
C47563
INN ID
7541

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound118984445https://pubchem.ncbi.nlm.nih.gov/compound/118984445
RxNorm51428https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=51428
NCI ThesaurusC47563https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47563
FDA Substance Registration SystemD933668QVXhttps://precision.fda.gov/uniisearch/srs/unii/D933668QVX

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
INSULIN ASPARTACTIVE MOIETYD933668QVXThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 ®2
INSULIN ASPARTACTIVE INGREDIENTD933668QVXThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 ®2
INSULIN ASPARTACTIVE MOIETYD933668QVXThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog ® (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 20001
INSULIN ASPARTACTIVE INGREDIENTD933668QVXThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog ® (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 20001
INSULIN ASPARTACTIVE INGREDIENTD933668QVXThese highlights do not include all the information needed to use NovoLog Mix 70/30 safely and effectively. See full prescribing information for NovoLog Mix 70/30. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Suspension for subcutaneous injection Initial U.S. Approval: 20012
INSULIN ASPARTACTIVE MOIETYD933668QVXThese highlights do not include all the information needed to use NovoLog Mix 70/30 safely and effectively. See full prescribing information for NovoLog Mix 70/30. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Suspension for subcutaneous injection Initial U.S. Approval: 20012
INSULIN ASPARTACTIVE INGREDIENTD933668QVXNOVOLOG (INSULIN ASPART) INJECTION, SOLUTION [NOVO NORDISK]19
INSULIN ASPARTACTIVE MOIETYD933668QVXNOVOLOG (INSULIN ASPART) INJECTION, SOLUTION [NOVO NORDISK]19
insulin aspartACTIVE MOIETYD933668QVXNOVOLOG MIX 70/30 (INSULIN ASPART) INJECTION, SUSPENSION [NOVO NORDISK]16
INSULIN ASPARTACTIVE INGREDIENTD933668QVXNOVOLOG MIX 70/30 (INSULIN ASPART) INJECTION, SUSPENSION [NOVO NORDISK]16